National Graphite Corp. is an exploration company, which engages in the exploration of gold, silver, and related minerals. The company is headquartered in Dusseldorf, Nordrhein-Westfalen. The company went IPO on 2009-06-30. The firm is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The firm operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.
최신 재무제표(Form-10K)에 따르면, National Graphite Corp의 총 자산은 $0이며, 순손실입니다.
NGRC의 주요 재무 비율은 무엇인가요?
National Graphite Corp의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
National Graphite Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
National Graphite Corp 주요 수익원은 Global Priority Brands이며, 최신 수익 발표에서 수익은 2,050,200,000입니다. 지역별로는 Americas이 National Graphite Corp의 주요 시장이며, 수익은 1,388,500,000입니다.
National Graphite Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 National Graphite Corp의 순손실은 $-1입니다.